Kunlun Capital
Kunlun Capital is an investment firm.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Kunlun Capital Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Kunlun Capital is a value-oriented and fundamentally driven family office. We do not manage external funds.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 12/2021 | CirCode | Seed Round | 20M |
| 12/2021 | Zhongke Digital | Series A | - |
| 4/2021 | EdiGene | Series B | 61.6M |
| 10/2021 | Danwang Medical | Series A | 18.6M |
| 3/2022 | UniXell | Seed Round | 0 |
| 12/2020 | NeoCura | Series A | 38.2M |
| 12/2021 | Circular Code Biology | Seed Round | 20M |
| 3/2021 | Nice Tuan | Series D | 0 |
| 4/2022 | Ningbo Shanshan | Post-IPO Equity | 0 |
| 3/2021 | Biotheus | Series B | - |
| 3/2022 | CellOrigin Biotech | Venture Round | 0 |
| 12/2021 | Zhongke Digital | Series A | - |
| 8/2021 | UniXell | Angel Round | - |
| 3/2022 | Nutshell Therapeutics | Series A | 0 |
| 5/2022 | Hui-Gene Therapeutics | Series C | - |
| 5/2022 | Hui-Gene Therapeutics | Series C | - |
| 4/2022 | Ningbo Shanshan | Post-IPO Equity | 0 |
| 3/2022 | CellOrigin Biotech | Venture Round | 0 |
| 3/2022 | Nutshell Therapeutics | Series A | 0 |
| 3/2022 | UniXell | Seed Round | 0 |
| 12/2021 | Zhongke Digital | Series A | - |
| 12/2021 | Circular Code Biology | Seed Round | 0 |
| 12/2021 | CirCode | Seed Round | 0 |
| 10/2021 | Danwang Medical | Series A | 0 |
| 8/2021 | UniXell | Angel Round | - |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
